BROSSARD, QUEBEC--(Marketwired - Sept. 3, 2014) - Diagnos Inc. ("DIAGNOS" or "the Corporation") (TSX VENTURE:ADK), a leader in healthcare technical services including screening, software and algorithm development, data analysis, and image processing, announced today the signing of a contract with a large global pharmaceutical company for a screening project in Turkey. According to the International Diabetes Federation, Turkey has a population of 74 million people with a diabetes prevalence of 14.6%, or about 10.8 million people.
"This is the third project we are starting with this pharmaceutical company within the past month. We have successful, well established screening programs with our pharmaceutical partner in the UAE and India, and we are now beginning to expand our services around the world with our partner. As of this moment, we have screening programs running concurrently in the UAE, India, Argentina, Turkey, and Eastern Europe with this client. We look forward to continue expanding our services within these countries and starting new projects in other diabetes plagued countries," said André Larente, Diagnos' President.
About DIAGNOS
Founded in 1998, DIAGNOS is a publicly traded Canadian corporation, with a mission to commercialize technologies to improving decision making processes in different sectors. DIAGNOS offers products, services, and solutions to clients in a variety of fields including healthcare and natural resources.
About DIAGNOS Healthcare
DIAGNOS Healthcare is a business division with DIAGNOS Inc., achieving international recognition as leader in healthcare technical services including, screening, software and algorithm development, data analysis, and image processing. Through its Healthcare division, DIAGNOS offers turn-key diabetic retinopathy screening services to patients in various locations around the world.
Diabetic retinopathy is the most common diabetic eye disease and a leading cause of blindness around the world. It is a treatable disease that, as with most diseases, has a higher treatment success rate in its earlier stages. However, there are generally no symptoms until the disease has progressed to more severe stages, making early detection critical to helping prevent vision loss.
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For further information on DIAGNOS, please visit our website at www.diagnos.com or the SEDAR website at www.sedar.com.
Contact Information:
President
DIAGNOS Inc.
(450) 678-8882 ext 224